Media Thread, page-17996

My quick ‘two cents’ on the poster session ...

Congrats to @Shornbra@AlCp@cjnav and @LHI14 ,along with the personal experiences of @MrLearner

I believe between you all, you have covered the key points and made many great observations.

Key takeaways for me...

• Just as effective as ‘the best’ Chemo but WITHOUT the side effects. This has to have value. (Who should be taking this to Big Pharma / Mid-Pharma now Monil has gone? It needs to be someone. Apart from their very ‘patchy’ communication, I am also concerned we don’t have enough happening with promotion to ‘buyers’. Do we still have a deal maker?)

• We should move forward with IT, clearly far more effective, as mentioned by the team above and noted clearly in the poster.

• We should have a look at IT in combo with Prembro. We need more data here, which may turn out to be compelling. To date we only have IV data and it is low dose.

• CF33 is performing exactly as Yuman predicted.

• Significant unmet market, as AlCp reminds us.

I’m off ... but looking forward to the Q & A. Fingers crossed that they have a go at some of the ‘harder’ questions and not just deal with the 'safer stuff’.

All, just my opinion.